Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC.
Richardson PG, et al. Among authors: mitsiades c.
Blood. 2002 Nov 1;100(9):3063-7. doi: 10.1182/blood-2002-03-0996.
Blood. 2002.
PMID: 12384400
Free article.
Clinical Trial.